Arkolith/Insider Trading/SYRS/Form 4

Haas Jason

Chief Financial OfficerSyros Pharmaceuticals, Inc. (SYRS) · full profile →Form 4 · filed Nov 4, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 31, 2024Tax withholding(F)6K$2.09$12K138K
Oct 31, 2024Option exercise(M)19K——143K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 31, 2024Option exercise(M)19K—$00

Transaction Codes

F
Shares withheld for taxes
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-120869) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML